Advancing Human Health & Performance

What if wearables could change lives? Orpyx® foot pressure measurement technologies includes wearable sensors used to improve human health and advance sports performance.

SurroSense Rx®

Limb loss isn’t inevitable. Help prevent diabetic foot ulcers and track progress. Get your feet back on track with the SurroSense Rx system.

Orpyx® LogR™

Accurate, efficient, and real-time measurement of foot and plantar pressure analysis. 100% mobile, durable and reusable, no tether, computer or lab required.

Recent News

New clinical trial provides further evidence of the SurroSense Rx® effectiveness of protecting people with diabetes from foot ulcers

The latest clinical trial by an award-winning research group out of Manchester Metropolitan University demonstrates that people with diabetes can reduce the risk of developing foot ulcers by more than 70 per cent using the SurroSense Rx intelligent shoe insoles that send alerts to a smartwatch notifying the device user when the pressure on a particular region of their foot gets outside a healthy range. The SurroSense Rx system, developed by Orpyx Medical Technologies Inc., is an FDA-cleared technology and commercially available for foot ulcer prevention to physicians across North America.

read more

Manchester Metropolitan University Receives Award at the Diabetic Foot Study Group Scientific Meeting

The oral presentation titled “Novel Plantar Pressure-Sensing Smart Insoles Reduce Foot Ulcer Incidence in ‘High Risk’ Diabetic Patients: A Longitudinal Study” was awarded the prestigious Paul Wilson Brand Repetitive Stress Award at the 15th annual meeting of the Diabetic Foot Study Group of the EASD (European Association for the Study of Diabetes), held in Berlin, Germany September 28 – 30, 2018.

read more

New Clinical Trial Evidence of SurroSense Rx® to be Presented at EASD 2018

Results from a randomized clinical trial ran by Manchester Metropolitan University showed the SurroSense Rx provided a 71 per cent reduction in foot ulcers over an 18-month long study. Manchester Metropolitan University will be presenting their findings at EASD 2018 (European Association for the Study of Diabetes) at the Messe Berlin Exhibition Halls in Berlin-Charlottenburg, Germany on October 2, 2018.

read more

Contact Us

info@orpyx.com
1.855.996.7799

U.S. Patent No. 10,004,428 - June 2018
U.S. Patent No. 9,778,131 B2 - October 2017
U.S. Patent No. D740,950 S - October 2015
Australia Patent No. 2011320072 - May 2016
Japan Patent No. 6004444 - October 2016
New Zealand Patent No. 611197 - November 2015

Subscribe to our newsletter
* indicates required